Wolfgang Jacob

Penzberg, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.

Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma.

Journal: Clinical pharmacology and therapeutics

Published: March 07, 2026

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.

Journal: Journal for immunotherapy of cancer

Published: March 08, 2022

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.

Journal: Journal for immunotherapy of cancer

Published: September 21, 2020

Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.

Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 29, 2020

An SEM compatible plasma cell for in situ studies of hydrogen-material interaction.

An SEM compatible plasma cell for in situ studies of hydrogen-material interaction.

Journal: The Review of scientific instruments

Published: May 03, 2020

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 23, 2019

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer.

Journal: ESMO open

Published: April 25, 2019

SIESTA: A high current ion source for erosion and retention studies.

SIESTA: A high current ion source for erosion and retention studies.

Journal: The Review of scientific instruments

Published: November 08, 2018

EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion.

EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 25, 2018

Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.

Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.

Journal: Cancer treatment reviews

Published: April 03, 2018

Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy.

Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy.

Journal: Molecular cancer therapeutics

Published: December 24, 2017

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.

Journal: Investigational new drugs

Published: December 21, 2017

Showing 1-12 of 19

Last Updated: 09/26/2026